Literature DB >> 22571338

High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.

Jimmy K Stauffer1, Rimas J Orentas, Erin Lincoln, Tahira Khan, Rosalba Salcedo, Julie A Hixon, Timothy C Back, Jun S Wei, Rajesh Patidar, Young Song, Laura Hurd, Maria Tsokos, Edwin W Lai, Graeme Eisenhofer, William Weiss, Javed Khan, Jon M Wigginton.   

Abstract

Using two MYCN transgenic mouse strains, we established 10 transplantable neuroblastoma cell lines via serial orthotopic passage in the adrenal gland. Tissue arrays demonstrate that by histochemistry, vascularity, immunohistochemical staining for neuroblastoma markers, catecholamine analysis, and concurrent cDNA microarray analysis, there is a close correspondence between the transplantable lines and the spontaneous tumors. Several genes closely associated with the pathobiology and immune evasion of neuroblastoma, novel targets that warrant evaluation, and decreased expression of tumor suppressor genes are demonstrated. These studies describe a unique and generalizable approach to expand the utility of transgenic models of spontaneous tumor, providing new tools for preclinical investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571338      PMCID: PMC6993178          DOI: 10.3109/07357907.2012.664670

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  107 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C.

Authors:  J L Cox; P S Sexton; T J Green; N A Darmani
Journal:  Melanoma Res       Date:  1999-08       Impact factor: 3.599

3.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.

Authors:  T Teitz; T Wei; M B Valentine; E F Vanin; J Grenet; V A Valentine; F G Behm; A T Look; J M Lahti; V J Kidd
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2.

Authors:  V Poulaki; N Mitsiades; M E Romero; M Tsokos
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 5.  Prospects for therapeutic inhibition of neuroblastoma angiogenesis.

Authors:  Suzanne Shusterman; John M Maris
Journal:  Cancer Lett       Date:  2005-10-18       Impact factor: 8.679

6.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Authors:  D J Good; P J Polverini; F Rastinejad; M M Le Beau; R S Lemons; W A Frazier; N P Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 7.  Antiangiogenic strategies in neuroblastoma.

Authors:  Domenico Ribatti; Mirco Ponzoni
Journal:  Cancer Treat Rev       Date:  2004-11-18       Impact factor: 12.111

Review 8.  Advances in the diagnosis and treatment of neuroblastoma.

Authors:  Joanna L Weinstein; Howard M Katzenstein; Susan L Cohn
Journal:  Oncologist       Date:  2003

9.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Authors:  D H Kaplan; V Shankaran; A S Dighe; E Stockert; M Aguet; L J Old; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.

Authors:  S Ikeyama; M Koyama; M Yamaoko; R Sasada; M Miyake
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  4 in total

1.  MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.

Authors:  Shile Zhang; Jun S Wei; Samuel Q Li; Tom C Badgett; Young K Song; Saurabh Agarwal; Cristian Coarfa; Catherine Tolman; Laura Hurd; Hongling Liao; Jianbin He; Xinyu Wen; Zhihui Liu; Carol J Thiele; Frank Westermann; Shahab Asgharzadeh; Robert C Seeger; John M Maris; Jamie M Guidry Auvil; Malcolm A Smith; Eric D Kolaczyk; Jason Shohet; Javed Khan
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

2.  Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.

Authors:  Michiel Kroesen; Ingrid C Brok; Daphne Reijnen; Maaike A van Hout-Kuijer; Ingrid S Zeelenberg; Martijn H Den Brok; Peter M Hoogerbrugge; Gosse J Adema
Journal:  Cancer Immunol Immunother       Date:  2015-02-17       Impact factor: 6.968

3.  Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Authors:  Samuel Q Li; Adam T Cheuk; Jack F Shern; Young K Song; Laura Hurd; Hongling Liao; Jun S Wei; Javed Khan
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

4.  Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden.

Authors:  Francesca Scrimieri; David Askew; David J Corn; Saada Eid; Iuliana D Bobanga; Jaclyn A Bjelac; Matthew L Tsao; Frederick Allen; Youmna S Othman; Shih-Chung G Wang; Alex Y Huang
Journal:  Oncoimmunology       Date:  2013-11-22       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.